Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MCLO-12
- Development stage
- Preclinical
- Modality
- Peptides
01
Overview
MCLO-12 is a septapeptide with the sequence FHGKGHE (Phe-His-Gly-Lys-Gly-His-Glu), isolated from the bitter melon plant (*Momordica charantia* L.). It has demonstrated anti-proliferative and pro-apoptotic activity against non-small cell lung cancer (NSCLC) cells in preclinical studies. The peptide's mechanism of action involves the suppression of the thioredoxin (Trx) system and the induction of intracellular reactive oxygen species (ROS). These actions trigger the activation of the ASK1, p38 MAPK, and JNK signaling pathways, leading to caspase activation and apoptosis in cancer cells.
- Other names
- FHGKGHEPhe-His-Gly-Lys-Gly-His-GluMomordica charantia L. oligopeptide-12
02
Targets
TXN (Thioredoxin-1)
Beyond the preview
Go deeper on MCLO-12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MCLO-12.